Premium
Thromboembolism prophylaxis in patients with Philadelphia‐negative myeloproliferative neoplasms—Clinical practice among Nordic specialists
Author(s) -
Bjerrum Ole Weis,
Samuelsson Jan,
Ghanima Waleed,
Kauppila Marjut,
Andersen Christen Lykkegaard
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13043
Subject(s) - medicine , phlebotomy , myeloproliferative neoplasm , polycythemia vera , family medicine , population , intensive care medicine , health care , myelofibrosis , bone marrow , environmental health , economics , economic growth
Background Patients with Philadelphia chromosome‐negative myeloproliferative neoplasms ( MPN s) have higher risks of developing thromboembolisms compared to the general population. International guidelines on the management of MPN s therefore include recommendations concerning thromboembolism prophylaxis. In clinical practice, strict adherence to guidelines may be challenging and dependent on factors such as physician experience, outpatient clinic setting, and access to therapy; however, no data exist on physician adherence or patient compliance to thromboembolism prophylaxis in MPN s. Objectives The Nordic Myeloproliferative Neoplasm Study Group ( NMPN ) performed a survey among Nordic hematology specialists with the aim of documenting the implementation of international recommendations in a region of Northern Europe with similar healthcare systems. Results The study showed that Nordic specialists managed their patients in accordance with international guidelines concerning medical intervention, but to a lesser degree regarding the management of additional cardiovascular risk factors. The survey also drew attention to the common clinical dilemma of combining antiaggregatory agents with vitamin K antagonists ( VKA ), or novel oral anticoagulants ( NOAC ), as well as phlebotomy limits in female polycythemia vera patients. Conclusions The results of this study highlight the importance of considering all risk factors for thrombosis and an optimal collaboration with the primary healthcare sector.